Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Melanoma 26Neuroblastoma 25Breast Neoplasms 20Prostatic Neoplasms 18Leukemia 15Multiple Myeloma 14Lymphoma 14Leukemia, Myeloid, Acute 14Glioblastoma 14Lymphoma, Non-Hodgkin 10Neoplasms 9Ovarian Neoplasms 8Neoplasm Metastasis 8Leukemia, Lymphocytic, Chronic, B-Cell 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms, Male 8Myelodysplastic Syndromes 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Glioma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Fallopian Tube Neoplasms 6Osteosarcoma 5Hodgkin Disease 5Carcinoma, Renal Cell 5Brain Neoplasms 5Uveal Melanoma 4Recurrence 4Rectal Neoplasms 4Medulloblastoma 4

Interventions

Cyclophosphamide 16Etoposide 14Carboplatin 11Temozolomide 10Vincristine 9Granulocyte Colony-Stimulating Factor 9Filgrastim 9Magnetic Resonance Spectroscopy 8Cisplatin 8etoposide phosphate 7X-Rays 7Thiotepa 7Phantoms, Imaging 7Methotrexate 7tazemetostat 6Topotecan 6Specimen Handling 6Radiotherapy 6Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Mesna 4Melphalan 4Biopsy 4palbociclib 3Sirolimus 3Nivolumab 3Leucovorin 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdoid Tumor × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡